Patients with type 2 diabetes inadequately controlled on premixed insulin: Effect of initiating insulin glargine plus oral antidiabetic agents on glycaemic control in daily practice

International Journal of Clinical Practice

Volumn 61, Issue 12, 2007, Pages 2009-2018

  Hammer, H ^a   Klinge, A ^b  

^a Hausärztliche Versorgung ^*  (Germany)

^b Facharzt für Pharmakologie und Innere Medizin   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; GLIMEPIRIDE; GLYCOSYLATED HEMOGLOBIN; INSULIN GLARGINE; METFORMIN; ORAL ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CONTROL; DRUG EFFECT; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERANCE; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; HYPERHIDROSIS; HYPOGLYCEMIA; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SELF MONITORING; STATISTICAL ANALYSIS; VALIDATION PROCESS; WEIGHT REDUCTION;

ADMINISTRATION, ORAL; AGED; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 35948970944     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01598.x     Document Type: Article

References (18)

1. Koivisto VA, Tuominen JA, Ebeling P. Lispro Mix25 insulin as premeal therapy in type 2 diabetic patients. Diabetes Care 1999 22 : 459 62.
2. Garber AJ. Premixed insulin analogues for the treatment of diabetes mellitus. Drugs 2006 66 : 31 49.
3. Roach P, Trautmann M, Arora V et al. Improved postprandial blood glucose control and reduced nocturnal hypoglycemia during treatment with two novel insulin lispro-protamine formulations, insulin lispro mix25 and insulin lispro mix50. Mix50 Study Group. Clin Ther 1999 21 : 523 34.
4. Janka HU, Plewe G, Riddle MC et al. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005 28 : 254 9.
5. sanofi-aventis. LANTUS: Summary of Product Characteristics, 2006. http://www.emea.europa.eu/humandocs/Humans/EPAR/lantus/lantus.htm (accessed May 2007).
6. Schreiber SA, Haak T. Insulin glargine benefits patients with type 2 diabetes inadequately controlled on oral antidiabetic treatment: an observational study of everyday practice in 12,216 patients. Diabetes Obes Metab 2007 9 : 31 8.
7. Hauner H, Koster I, von Ferber L. Outpatient care of patients with diabetes mellitus in 2001. Analysis of a health insurance sample of the AOK in Hesse/KV in Hesse. Dtsch Med Wochenschr 2003 128 : 2638 43.
8. Larger E. Weight gain and insulin treatment. Diabetes Metab 2005 31 (4 part 2 4S51 6.
9. Raskin P, Allen E, Hollander P et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005 28 : 260 5.
10. Schreiber SA, Russmann A. Insulin glargine and educational intervention in patients with type 2 diabetes in clinical practice: long-term improvement in glycaemic control without weight gain. Exp Clin Endocrinol Diabetes 2006 114 : 41 2.
11. Zammitt NN, Frier BM. Hypoglycemia in type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care 2005 28 : 2948 61.
12. Rosenstock J, Schwartz SL, Clark CM Jr. et al. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001 24 : 631 6.
13. Yki-Jarvinen H, Kauppinen-Makelin R, Tiikkainen M et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 2006 49 : 442 51.
14. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003 26 : 3080 6.
15. IDF Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes. Brussels : International Diabetes Federation, 2005.
16. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2006 29 (Suppl. 1 S4 42.
17. Eliaschewitz FG, Calvo C, Valbuena H et al. Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride. Arch Med Res 2006 37 : 495 501.
18. Raccah D, Bretzel RG, Owens D, Riddle M. When basal insulin therapy in type 2 diabetes mellitus is not enough - what next? Diabetes Metab Res Rev 2007 23 : 257 64.